Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × tisagenlecleucel × Clear all
NCT04456023 2022-03-02

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Novartis

Phase 2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡